Aimmune Therapeutics Inc. (AIMT)

24.21
0.63 2.67
NASDAQ : Health Technology
Prev Close 23.58
Open 23.75
Day Low/High 23.14 / 24.23
52 Wk Low/High 21.22 / 42.00
Volume 812.11K
Avg Volume 685.40K
Exchange NASDAQ
Shares Outstanding 58.73M
Market Cap 1.40B
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Facebook Is Today's Star as Pockets of Strong Momentum Grow

Facebook Is Today's Star as Pockets of Strong Momentum Grow

It is the action in secondary stocks that is giving the action a much better feel.

There Are a Number of Justifications For Friday's Market Strength

There Are a Number of Justifications For Friday's Market Strength

Regardless of what is moving the markets, it is a good example of how you have to focus on price action above all else.

Aimmune Therapeutics Appoints Andrew Oxtoby As Chief Commercial Officer

Aimmune Therapeutics Appoints Andrew Oxtoby As Chief Commercial Officer

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Andrew Oxtoby as Chief Commercial Officer.

Starbucks, Square, Alibaba: 'Mad Money' Lightning Round

Starbucks, Square, Alibaba: 'Mad Money' Lightning Round

Jim Cramer weighs in on Starbucks, Square, Alibaba, ArcelorMittal, Dynavax Technologies, Aimmune Therapeutics, Clearway Energy and more.

Breaking Down Citigroup Earnings: Cramer's 'Mad Money' Recap (Monday 1/14/19)

Breaking Down Citigroup Earnings: Cramer's 'Mad Money' Recap (Monday 1/14/19)

We may be so worried about the state of the global economy that we're missing some great opportunities, Jim Cramer says.

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

The stock's decline with the sector has occurred despite a steady supply of positive news.

The Market Is Transitioning Back to Stock Picking

The Market Is Transitioning Back to Stock Picking

There are obvious signs that people are trying to put cash to work.

Aimmune Therapeutics And KKR Enter Into $170M Loan Agreement To Fund AR101 Commercialization And Pipeline Advancement

Aimmune Therapeutics And KKR Enter Into $170M Loan Agreement To Fund AR101 Commercialization And Pipeline Advancement

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global...

Aimmune Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7th

Aimmune Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas, M.

Quiet Trading Allowing Some Biotech Names to Perk Up

Quiet Trading Allowing Some Biotech Names to Perk Up

After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.

February 2019 Options Now Available For Aimmune Therapeutics (AIMT)

February 2019 Options Now Available For Aimmune Therapeutics (AIMT)

Investors in Aimmune Therapeutics Inc saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new February 2019 contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics Submits BLA To FDA For AR101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4-17

Aimmune Therapeutics Submits BLA To FDA For AR101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4-17

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a Biologics License Application (BLA) to the U.

No Market for Old Stock Pickers

No Market for Old Stock Pickers

As long as the indices remain under pressure there is no benefit to picking stocks.

Aimmune Therapeutics Announces IND Filing For AR201 For Egg Allergy And Exclusive Supply Agreement With Michael Foods

Aimmune Therapeutics Announces IND Filing For AR201 For Egg Allergy And Exclusive Supply Agreement With Michael Foods

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the submission of its investigational new drug (IND) application for AR201 for the treatment of...

Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial For Treatment Of Peanut Allergy In 1-3-Year-Old Children

Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial For Treatment Of Peanut Allergy In 1-3-Year-Old Children

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON ( Peanut Oral Immunotherapy Study of Early Intervention for...

Aimmune Therapeutics To Host Investor Symposium On The Future Of Treating Peanut Allergy With Leading Expert Allergists On Wednesday, December 12th

Aimmune Therapeutics To Host Investor Symposium On The Future Of Treating Peanut Allergy With Leading Expert Allergists On Wednesday, December 12th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018.

What We Have This Morning Is Some Routine Flipping Into Strength

What We Have This Morning Is Some Routine Flipping Into Strength

My overall market view right now is to maintain a bullish bias but look for some pullbacks to support.

I'm Surprised by How Lifeless the Action Is

I'm Surprised by How Lifeless the Action Is

I find it difficult to believe that there won't be something positive out of the G-20 meeting.

Aimmune Therapeutics Announces Closing Of $98 Million Investment By Nestlé Health Science

Aimmune Therapeutics Announces Closing Of $98 Million Investment By Nestlé Health Science

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science.

First Week Of AIMT January 2019 Options Trading

First Week Of AIMT January 2019 Options Trading

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

AIMT: Insiders Vs. Shorts

AIMT: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Aimmune Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 14.17 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Kohl's Stock Finds Itself Under Heavy Pressure

Kohl's Stock Finds Itself Under Heavy Pressure

The problem KSS faces is that reports from retailers are being automatically sold in this poor market right now.

Landmark PALISADE Trial Of AR101 Published In New England Journal Of Medicine

Landmark PALISADE Trial Of AR101 Published In New England Journal Of Medicine

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the New England Journal of Medicine ( NEJM) has published the full results of the landmark...

Aimmune Therapeutics Announces Additional Equity Investment By Nestlé Health Science

Aimmune Therapeutics Announces Additional Equity Investment By Nestlé Health Science

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $98 million,...

Aimmune Therapeutics Announces Third Quarter 2018 Financial Results And Recent Corporate Highlights

Aimmune Therapeutics Announces Third Quarter 2018 Financial Results And Recent Corporate Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2018.

Aimmune Therapeutics Announces Presentations At 2018 ACAAI Annual Scientific Meeting

Aimmune Therapeutics Announces Presentations At 2018 ACAAI Annual Scientific Meeting

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy and peanut allergy at the American College...

Aimmune Therapeutics Announces Appointment Of Dr. Brett Haumann To Board Of Directors

Aimmune Therapeutics Announces Appointment Of Dr. Brett Haumann To Board Of Directors

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.

Aimmune Therapeutics To Participate In Upcoming Investor Conferences

Aimmune Therapeutics To Participate In Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences: Stifel 2018...